Drug Discovery World

OCTOBER 3, 2023

Earlier this year, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. This all creates numerous challenges for the market. For the AAV packaging service, what is the titer of the viral particles? Why are those important?

Therapies 130

Therapies Bioinformatics Packaging Molecular Biology 130

Drug Discovery World

FEBRUARY 8, 2024

In 2023, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. This all creates numerous challenges for the market. For the AAV packaging service, what is the titer of the viral particles? Why are those important?

Therapies 148

Therapies Bioinformatics Packaging Molecular Biology 148

Agency IQ

APRIL 12, 2024

In an effort to further explain its current views on potency assurance, the FDA also recorded a webinar to accompany the new draft. Additionally, six of these comments came from the same organization (Integrated DNA Technologies). What does progressive implementation of a potency assurance strategy mean? If so, how?

Production 40

Production FDA Therapies Biochemical Assays 40

Agency IQ

MARCH 29, 2024

EPA also held a public webinar to provide an overview of the TSCA risk management process including the findings in the Part 1 risk evaluation. In addition, EPA published a notice of data availability on March 17, 2023 to solicit public comments on additional data received by EPA related to the proposed rule.

Regulations 40

Regulations Compliance Production Government 40